The neutral proteinase collagenase is the only enzyme initiating breakdown of the interstitial collagens, Tupes I, II, and III, the body's most abundant structural proteins. Collagen remodeling occurs in normal processes, such as uterine resorption and wound healing, and in pathophysiological conditions, such as tumor invasion and rheumatoid arthritis. Nowhere is the impact of collagenase more apparent than in this latter disease where there is gross destruction of cartilage, tendon and bone, with subsequent deformity and loss of joint function. Our work focuses on mechanisms operating at the level of the gene to control collagenase production in rheumatoid arthritis. For these studies, we use a model system of monolayer cultures of rabbit synovial fibroblasts. These cells are readily available, grow well in culture, and importantly, can be induced to synthesize and secrete large quantities of collagenase, Mr. 57K and 61K. Equally attractive is the fact that collagenase synthesis can be suppressed by glucocorticoids or the synthetic Vitamin A analogues, the retinoids. Along with collagenase, another protein, Mr 52K and 54K, that functions to activate latent collagenase is also induced and repressed. Both inducers and repressors appear to affect collagenase and its activator by acting transcriptionally. Confirmation of this hypothesis is one aim of this proposal. Our studies to date have resulted in the isolation and characterization of both cDNA and genomic clones for synovial cell collagenase and these are appropriate tools for extending our work. Specifically, we will (1) determine whether steroids and retinoids affect collagenase mRNA 1/2 life; (2) isolate the 5' end of the collagenase gene and characterize its promoter regions; (3) study the coordinate regulation of collagenase and its activator protein by isolating and characterizing cDNA and genomic clones for this activator; (4) determine the chromosomal location(s) for the rabbit synovial cell collagenase gene(s) so as to investigate the genetic basis for multiple forms of collagenase protein (e.g., macrophage, neutrophil, synovial cell collagenase); and (5) sequence the cDNA and genomic clones for collagenase and its activator. Results of these studies are important to our understanding not only of how the destructive potential of synovial cells is regulated in rheumatoid arthritis but also to the control of collagenolysis by various other cell types throughout the body.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR026599-09
Application #
3155437
Study Section
Molecular Biology Study Section (MBY)
Project Start
1980-03-01
Project End
1989-02-28
Budget Start
1988-03-01
Budget End
1989-02-28
Support Year
9
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Brinckerhoff, Constance E (2017) Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire? J Cell Physiol 232:2674-2678
Brinckerhoff, Constance E (2016) What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib? Melanoma Manag 3:5-8
Jenkins, Molly H; Croteau, Walburga; Mullins, David W et al. (2015) The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biol 48:66-77
Whipple, Chery A (2015) Tumor talk: understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron 2:e773
Jenkins, Molly H; Steinberg, Shannon M; Alexander, Matthew P et al. (2014) Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res 27:495-501
Whipple, C A; Brinckerhoff, C E (2014) BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer 111:1625-33
Croteau, Walburga; Jenkins, Molly H; Ye, Siying et al. (2013) Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J Cell Physiol 228:773-80
Schmucker, Adam C; Wright, Jason B; Cole, Michael D et al. (2012) Distal interleukin-1? (IL-1?) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression. J Biol Chem 287:1189-97
Zhou, Jing; Brinckerhoff, Constance; Lubert, Susan et al. (2011) Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors. Cancer Invest 29:599-607
Blackburn, J S; Liu, I; Coon, C I et al. (2009) A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 28:4237-48

Showing the most recent 10 out of 86 publications